AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic...


TOKYO and XIAMEN, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”), an in vitro diagnostic reagent developed as a companion diagnostic for multiple anti-cancer agents, was approved by Ministry of Health, Labour and Welfare (MHLW) for production and marketing in Japan on June 25, 2021.


Read the full press release below:

RG_JointRelease_0630-2021 FINAL.docx
.pdf
Download PDF • 114KB